# CURRICULUM VITAE

# Dr ANKE ERMA HENSIEK, Dr. med., FRCP, PhD

E-Mail: ahensiek@nhs.net

PA (Ms Kayleigh Shough): kayleigh.shough@nhs.net

# **Profile/Summary:**

- Consultant Neurologist Addenbrookes Hospital, Cambridge and Queen Elizabeth Hospital, Kings Lynn
- Excellent broad clinical experience in general neurology
- Strong academic background and continuing interest in clinical research
- Subspecialty interest in clinical neurogenetics, including involvement in National service provision for neurofibromatosis type 2 and ataxia telangiectasia
- Mediccolegal experience since 2009 including personal injury, negligence reports and work for GMC

### Content:

-	Personal details and qualifications:	2
-	Membership of professional organizations	2
-	Scholarships and Awards	3
-	Education	3
-	Previous posts	3
-	Clinical experience	5
-	Research	5
-	Medicolegal experience	6
-	Terms and conditions	6
_	Publications	7

### Personal details:

Date of Birth: April 15<sup>th</sup>, 1966

Nationality: British and German

# Medical qualifications:

- German Staatsexamen (1994), University of Duesseldorf, Germany. Passed with "excellent"

- German "Doctor Medicinae" (1997), University of Duesseldorf, "Magna Cum Laude"
- FMGEMS (Foreign Medical Graduate Exam) part 1 (1992), USMLE (United Stated Medical Licensing Exam) part 2 (1994)
- MRCP part 1 (June 1996); MRCP part 2 (June 1998)
- Doctor of Philosophy (May 2004), University of Cambridge

**GMC registration:** Full registration, No 4342962

**Date of CCT completion:** March 18, 2008

### Membership of professional organizations:

- Fellow of Royal College of Physicians London
- Association of British Neurologists
- European Academy of Neurology
- British Medical Association

### **Current post:**

**Consultant Neurologist** 

Addenbroookes Hospital Hills Road Cambridge CB2 2QQ

Queen Elizabeth Hospital Gayton Road Kings Lynn PE30 4ET

## **SCHOLARSHIPS AND AWARDS**

Beverly and Sackler Scholarship 2000, 2001, 2002

Wellcome Research Training Fellowship 1999
Clinical Excellence Award level 3 2018

### **EDUCATION**

#### **General Education:**

1973 - 1985 Primary and secondary school in

Buende, Germany

**Medical Education:** 

1986 - 1994 Medical School of the University of

Duesseldorf, Germany

**Undergraduate Research** 

1990 – 1993 "Event related potentials (P 300) in

asymptomatic HIV-patients"

Department of Neurology, University of

Duesseldorf, Germany

## **PREVIOUS APPOINTMENTS**

### **Internship:**

House Physician 2/1995 – 8/1995

Monklands Hospital Airdrie ML6 OJS

House Physician/Surgeon 8/1995 – 8/1996

North Middlesex Hospital

London, N18 1QX

**Senior House Officer:** 

SHO Neurology /Neurosurgery 8/1996 - 2/1997

SHO Rotation General Medicine/Neurology 2/1997 – 2/1999

Oldchurch Hospital

#### Romford, Essex RM7 OBE

## Senior House Officer Neurology

5/1999 - 11/1999

The National Hospital for Neurology and Neurosurgery Queen Square, London WC1N 3BG

### Research:

Wellcome Research Training Fellow

"Searching for susceptibility genes in Multiple Sclerosis"

Cambridge University Dep. for Clinical Neuroscience 12/1999 – 10/2003

# **Specialist Registrar**

Specialist Registrar Neurology
Norfolk and Norwich University Hospital

Colney Lane, Norwich

11/2003 – 6/2004

02/2006 – 9/2006; 2/2008

Specialist Registrar Neurology
The National Hospital for Neurology and Neurosurgery
Queen Square, London WC!N 3DG

7/2004 – 5/2005 10/2007 – 1/2008

Specialist Registrar Neurology Addenbrooke's Hospital Hills Road, Cambridge CB2 2QQ

5/2005 – 1/2006

10/2006 - 11/2006; 6/2007 - 9/2007

## Consultant

Consultant Neurologist

Since 3/2008

Addenbroookes Hospital Hills Road Cambridge

Queen Elizabeth Hospital Colney Lane Kings Lynn

### **Consulting Rooms**

The Cambridge Spire Lea Hospital, Cambridge

The Sandringham BMI Hospital, Gayton Road, Kings Lynn

## **CLINICAL EXPERIENCE**

I have excellent experience in general medicine as well as clinical and academic neurology. My current post as a consultant neurologist since 2008 involves assessing patient on an outpatient and inpatient basis, as well as on the intensive care unit. In my clinical practise I manage patients with all common and rare neurological disorders, including epilepsy, headinjury, headache, pain, dizziness, Parkinson's Disease, neuropathies, memory problems, muscle diseases, movement disorders and Multiple Sclerosis. Whilst the majority of my work involves general neurology, I have a subspecialty interest in neurogenetics and I conduct specialised neurogenetics clinics in Cambridge, including clinics on hereditary spastic paraparesis., ataxia and tuberous sclerosis. Furthermore, I am the neurology lead for national clinics for Neurofibromatosis type 2 and ataxia teleangiectasia and contribute to the development for assessment protocols and clinical studies into these disorders.

### RESEARCH:

I have experience in organising and conducting both clinical and basic research. I obtained the academic title 'Dr med' for completing a neurophysiological study on HIV-patients in Germany. In the UK, I was successful in obtaining a Wellcome Research Training Fellowship to work on the genetics of multiple sclerosis at the University of Cambridge. I completed several laboratory based genetic studies and am familiar with a range of genetic techniques as well as statistic methods for genetic analysis. I was awarded a PhD at the University of Cambridge in 2004. Since completing my period of full-time research, I have continued to be involved in clinical research which enhances and complements my work as a clinical neurologist. This includes being a member of the Scientific Advisory Board for the Ataxia Telangiectasia society as well as supervising PhD students and participating in clinical research and trials relating particularly to my special areas of interest.

#### **MEDICOLEGAL EXPERIENCE**

I have personal injury and medical negligence experience since 2009 and currently receive an average of 60 instructions per year, which comprise of roughly 80% claimant and 20% defendant reports. I also prepare reports for the General Medical Concil. Attendance at court as required.

#### MEDICLEGAL COURSES ATTENDED

Standard medico-legal course, London, 2010

Medico-legal court room skills course, London, 2015

### **TERMS AND CONDITIONS**

My current hourly rate is £240 per hour spent on the case. In addition, administrative support will be charged separately at the hourly rate of £20 for all time spent on the case. Itemised billing and copies of receipts will be provided if requested.

Draft report produced within two to six weeks (depending on complexity).

Report for court completed two weeks following return of draft.

Attendance at court will be charged at a daily rate of £1,600. I will require at least eight weeks notice for attendance at court hearing and any cancellations of less than 4 weeks notice will be charged at the full rate. Travel time will be charged at £100 per hour in addition to reimbursement of travel expenses, overnight stays will be charged at £300 per night in addition to reimbursement of hotel expenses.

I reserve the right to charge a non-attendance fee of £300 for cancellations of less than 24 hour's notice or non-attendance.

My report will only include review of medical records that have been received by the time of the scheduled outpatient appointment. Any medical records that are received after assessment of client and completion of my report will be assessed as part of an addendum report which would incur an additional fee.

Should accounts not be settled within four months of invoice, at my discretion, I have the right to charge interest on unpaid accounts at the rate of 2% a month, or part of a month, until full settlement is received.

### **PUBLICATIONS:**

### A. Articles

Teng M, Horvath R, **HensiekA:** Ataxia Telangiectasia – what the neurologist needs to know. Prect Neurol 2020, in press

Schon K, van Os N, Oscroft N, Baxendale H, Scoffings D, Ray J, Suri M, Whitehouse WP, Mehta PR, Everett N, Bottolo L, van de Warrenburg BP, Byrd PJ, Weemaes C, Willemsen MA, Tischkowitz M, Taylor AM, **Hensiek AE.**: Genotype, extrapyramidal features and severity of variant Ataxia-Telangiectasia. Ann Neurol. 2019, 85(2):170-180

van Os NJH, **Hensiek A**, van Gaalen J, Taylor AMR, van Deuren M, Weemaes CMR, Willemsen MAAP, van de Warrenburg BPC. Trajectories of motor abnormalities in milder phenotypes of ataxia telangiectasia. Neurology. 2019 Jan 1:92:e19-e29

**4**Morris, KA, Afridi, S, Evans G, **Hensiek A**, Kellet, M, Halliday D, Pretorius P, Parry A: The response of spinal cord Ependymomas to Bevacizumab in patients with Neurofibromatosis type 2. J Neurosurg Spine. 2016 Dec 16:1-9

**Hensiek AE**, Taylor AMR: The clinical variability of Ataxia Telangiectasia – an update. ACNR 2015; 15(2): 8- 12

**Hensiek A**, Kirker S, Evan E: Diagnosis, investigation and management of hereditary spastic paraplegia in the era of next generation sequencing. J Neurol 2015; 262 (7): 1601 - 12

Tysome JR, Macfarlane R, Durie-Gair J, Donnelly N, Mannion R, Knight R, Harris F, Vanat ZH, Tam YC, Burton K, **Hensiek A**, Raymond FL, Moffat DA, Axon PR. Surgical management of vestibular schwannomas and hearing rehabilitation in neurofibromatosis type 2. Otol Neurotol. 2012 Apr;33(3):466-72

**Hensiek AE**, Seaman SR, Barcellos L, Oturai A, Eraksoi M, Cocco E, Vecsei L, Steward G, Dubois B, Bellman-Strobl J, Leone M, Anderson O, Bencsik K, Booth D, Celius EG, Harbo H, Hauser S, Heard R, Hillert J, Myhr KM, Marrosu MG, Oksenberg J, Rajda C, Sawcer SJ, Soelberg Sørensen P, Zipp F, Compston DAS. Familial effects on the clinical course of multiple sclerosis. Neurology 2007, 30;68(5):376-83

**Hensiek AE**, Absalom T: Status epilepticus. Anaestheasia and Intensive Care medicine 2006. 7 (4); 127-128

Vera J, **Hensiek A**, Woodrow C, Crawley F, Krishna S: Ophthalmoplegia and slurred speech in an intravenous drug user, PLoS Medicine 2006, 3(12):e453

The Games Collaborative Group, Ban M, Booth D, Heard R, Stewart G, Goris A, Vandenbroeck K, Dubois B, Laaksonen M, Ilonen J, Alizadeh M, Edan G, Babron MC, Brassat D, Clanet M, Cournu-Rebeix I, Fontaine B, Semana G, Goedde R, Epplen J, Weber A, Infante-Duarte C, Zipp F, Rajda C, Bencsik K, Vécsei L, Heggarty S, Graham C, Hawkins S, Liguori M, Momigliano-Richiardi P, Caputo D, Grimaldi LM, Leone M, Massacesi L, Milanese C, Salvetti M, Savettieri G, Trojano M, Bielecki B, Mycko MP, Selmaj K, Santos M, Maciel P, Pereira C, Silva A, Silva BM, Coraddu F, Marrosu MG, Akesson E, Hillert J, Datta P, Oturai A, Harbo HF, Spurkland A, Goertsches R, Villoslada P, Eraksoy M, Hensiek A, Compston A, Setakis E, Gray J, Yeo TW, Sawcer: Linkage disequilibrium screening for multiple sclerosis implicates JAG1 and POU2AF1 as susceptibility genes in Europeans, J Neuroimmunol. 2006 Oct;179(1-2):108-16.

Roxburgh RH, Sawcer S, Maranian M, Seaman S, **Hensiek A**, Yeo T, Geans J, Compston A: No ecidence for a significant role of CTLA-4 in multiple sclerosis. J Neuroimmunol 2006, 171 (1-2); 193 – 197

1Roxburgh RH, Seaman SR, Mastermann T, **Hensiek AE**, Sawcer SJ, Vukusic S, Achiti I, Confavreaux C, Coustans M, lePage E, Edan G, McDonnel GV, Hawkins S, Trojano M, Liguri M, Cocco E, Marrosu MG, Teser F, Leone MA, Weber A, Zipp F, Miterski B, Epplen JT, Oturai A, Sorensen PS, Celius EG, Lara NT, Montalban X, Villoslada P, Silva AM, Marta M, Leite I, Dubois B, Butzkueven H, Kilpatrick T, Mycko MP, Selmaj KW, Rio ME, Sa M, Salemi G, Hillert J, Compston DA. Multiple Sclerosis Severity Score: using disability and disease duration to rate severity. Neurology 2005; 64 (7): 1144 - 1151

**Hensiek AE**, Roxburgh R, Smilie B, Coraddu F, Akesson E, Holman P, Sawcer SJ, Compston DAS. Updated results of the United Kingdom linkage based genome screen in multiple sclerosis. J Neuroimmunol 2003, 143 (1-2): 25 - 30

Åkesson E, Coraddu F, Marrosu M, Massacesi L, **Hensiek A**, Harbo HF, Oturai A, Trojano M, Momigliano-Richiardi P, Cocco E, Murru R, Hillert J, Compston DAS, Sawcer SJ. Refining the linkage analysis on chromosome 10 in 449 sib-pairs with multiple sclerosis. J Neuroimmunol 2003; 143 (1-2): 31-38

Yeo TW, Roxburgh R, Maranian M, Singlehurst S, Gray J, **Hensiek A**, Setakis E, Compston A, Sawcer S. Refining the analysis of a whole genome linkage disequilibrium association map: the United Kingdom. J Neuroimmunol 2003,; 143 (1-1): 53 – 59

Weber A, Infante-Duarte C, Sawcer S, Setakis E, Bellmann-Strobl J, **Hensiek A**, Rueckert S, Schoenemann C, Benediktsson K, Compston DAS, Zipp F. A genome-wide German screen for linkage disequilibrium in multiple sclerosis. J Neuroimmunol 2003, 143 (1-2): 79 - 83

Eraksoy M\*, **Hensiek A**\*, Kürtüncü M, Akman-Demir G, Kılınc M, Gedizlioglu M, Petek-Balcı B, Anlar O, Kutlu C, Saruhan-Direskeneli G, İdrisoglu HA, Setakis E, Compston A, Sawcer S & The Turkish Multiple Sclerosis Genetics Study Group. A genome screen for linkage disequilibrium in Turkish multiple sclerosis. J Neuroimmunol 2003, 143 (1-2): 129 - 132

**Hensiek AE,** Roxburgh R, Meranian M, Seaman S, Yeo T, Compston DA, Sawcer SJ: Osteopontin gene and clinical severity of multiple sclerosis. J Neurol 2003, 250(8):943-7

**Hensiek AE**, Compston DA, Sawcer SJ: Searching for needles in haystacks-the genetics of multiple sclerosis and other common neurological diseases. Brain Res Bull. 2003; 15;61(3):229-34.

Sawcer S, Maranian M, **Hensiek A**, Roxburgh R, Gray J, Compston A.: Crohn's associated NOD2 gene variants are not involved in determining susceptibility to multiple sclerosis. J Neurol Neurosurg Psychiatry 2003; 74 (8): 1157

**Hensiek AE,** Sawcer SJ, Feakes R, Deans J, Mander A, Akesson E, Roxburgh R, Coraddu F, Smith S, Compston DA.: HLA-DR 15 is associated with female sex and younger age at diagnosis in multiple sclerosis.. J Neurol Neurosurg Psychiatry. 2002;72 (2):184-7

Sawcer S, I Maranian M, Setakis E, Val Curwen V, Akesson E, **Hensiek A**, Coraddu F, Roxburgh R, Sawcer D, Gray J, Deans J, Goodfellow PN, Walker N, Clayton D, Compston A.: A whole genome screen for linkage disequilibrium in multiple sclerosis confirms disease associations with regions previously linked to susceptibility. Brain 2002, 125: 1337 – 1347

**Hensiek AE**, Trimble MR. Relevance of new psychotropic drugs for the neurologist. J Neurol Neurosurg Psychiatry. 2002;72(3):281-5.

Coraddu F, Sawcer S, D'Alfonso S, Lai M, **Hensiek A**, Solla E, Broadley S, Mancosu C, Pugliatti M, Marrosu MG, Compston A.: A genome screen for multiple sclerosis in Sardinian multiplex families. Eur J Hum Genet. 2001;9 (8):621-6

Broadley S, Sawcer S, D'Alfonso S, **Hensiek A**, Coraddu F, Gray J, Roxburgh R, Clayton D, Buttinelli C, Quattrone A, Trojano M, Massacesi L, Compston A. A genome screen for multiple sclerosis in Italian families. Genes Immun. 2001 Jun;2(4):205-10

**Hensiek AE**, Kellerman AJ, Hill JT.: Spontaneous regression of a solitary cerebral metastases in renal carcinoma and meningioma development under Medroxyprogesterone Acetate therapy . Br J Neurosurg 2000; 14 (4): 354 – 356

### B. Book chapters

Trimble MR, **Hensiek AE:** On the use of psychotropic drugs in patients with seizure disorders. In: The Neuropsychiatry of Epilepsy. EDS Trimble M, Schmitz BE, Cambridge University Press, 2003,

**Hensiek AE,** Roxburgh R, Compston DAS: Genetic epidemiology of multiple sclerosis. In: Neurology Blue Book series 2, EDS McDonald WI, Noseworthy J, Butterworth 2003